Ximing Ding

Ximing Ding is an Associate and Investment Manager at Pureos Bioventures, a venture capital firm dedicated to funding innovative drug development companies. In this capacity, he evaluates and executes venture capital investments in early to clinical-stage biotechnology startups that are developing next-generation biological therapies and novel formats. His investment scope spans multiple therapeutic areas, with a primary emphasis on oncology, immunology, ophthalmology, rare diseases, and neuroscience. Ding works alongside firm leadership, including Managing Partner Dominik Escher and founders Klaus Breiner and Martin Münchbach, to support portfolio companies through their clinical development phases. Additionally, he recently served as a moderator for emerging biotechnology company presentations at the Swiss Biotech Day conference on May 5. His current focus remains on identifying and capitalizing early-stage biopharmaceutical ventures targeting severe diseases with high unmet medical needs.